Amgen (NASDAQ:AMGN) Sets New 52-Week High – Here’s What Happened

Shares of Amgen Inc. (NASDAQ:AMGN) hit a new 52-week high on Tuesday . The stock traded as high as $391.29 and last traded at $385.70, with a volume of 2837817 shares trading hands. The stock had previously closed at $388.16.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board declared a $2.52 per‑share dividend for Q2 2026 — a cash return and yield support that tends to be received positively by income and value investors. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen advanced its blinatumomab franchise with a new Phase 3 subcutaneous trial — if successful, a subcutaneous formulation can broaden use, improve patient convenience, and extend commercial life. This is a clinically material development for future revenue potential. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Positive Sentiment: Stock reached an annual high within a Nasdaq‑100 rally — positive technical momentum and index strength can attract flows and lift shares. Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally
• Neutral Sentiment: Broader media and analyst coverage (Zacks, Yahoo Finance pieces) is raising investor attention but contains mainly summaries and guidance rechecks rather than new fundamental catalysts. Increased coverage can boost trading volume and visibility. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Industry and market reports (asthma market outlook, competitor regulatory moves) are circulating; these are background items to monitor for longer‑term impact but not immediate stock drivers. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Short‑interest entries in recent feeds report a “significant increase” but show zero shares/NaN figures — this appears to be a data error rather than a genuine surge in shorting. Until reliable short‑interest data is available, treat these reports cautiously. (Data entries from March 3–4 appear inconsistent.)

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Royal Bank Of Canada boosted their price objective on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Daiwa Securities Group lifted their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Truist Financial raised their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Finally, Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $354.17.

Amgen Stock Performance

The company has a 50-day moving average of $351.83 and a 200-day moving average of $321.58. The firm has a market capitalization of $204.45 billion, a price-to-earnings ratio of 26.65, a price-to-earnings-growth ratio of 3.74 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the firm earned $5.31 earnings per share. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Institutional Investors Weigh In On Amgen

Large investors have recently added to or reduced their stakes in the stock. High Note Wealth LLC boosted its stake in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the period. TAGStone Capital Inc. increased its stake in shares of Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 28 shares during the period. Verus Capital Partners LLC raised its holdings in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after buying an additional 28 shares during the last quarter. Destination Wealth Management boosted its position in shares of Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after buying an additional 29 shares during the period. Finally, West Family Investments Inc. grew its holdings in Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.